Pfizer appeals on anti-kickback case; Chinese rare disease biotech enlists UW to research Duchenne gene therapies
Last month, a judge told Pfizer that the pharma giant cannot pay out-of-pocket costs for Medicare patients to buy the company’s $225,000-a-year heart drug tafamidis. That was because, according to the judge, the move would violate federal kickback law.
And on Friday, Pfizer appealed the ruling — according to a filing in the US District Court for the Southern District of New York.
However the Pfizer case turns out, it will have implications for other companies moving forward — such as Biogen, after they agreed to pay $22 million last year for using foundations to pay co-pays for their MS drugs Avonex and Tysabri.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.